Verve Therapeutics shareholders elect Class I directors, ratify auditor, approve executive compensation

Verve Therapeutics, Inc.

Lonnel Coats, Jodie Morrison, Krishna Yeshwant elected Class I directors for three-year term ending 2028.
Ratification of Ernst & Young as auditor for FY2025: 72.8M for, 75.5K against, 237.9K abstain.
Advisory say-on-pay approved: 56.2M for, 2.7M against, 478.4K abstain, 13.7M broker non-votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.